### **POSTER PRESENTATION**

**Open Access** 

# P05.50. CONSORT extension for N-of-1 trials (CENT) guidelines

L Shamseer<sup>1</sup>, M Sampson<sup>2</sup>, C Bukutu<sup>5</sup>, N Barrowman<sup>2</sup>, D Altman<sup>3</sup>, D Moher<sup>4</sup>, S Vohra<sup>5\*</sup>

*From* International Research Congress on Integrative Medicine and Health 2012 Portland, Oregon, USA. 15-18 May 2012

#### **Purpose**

N-of-1 trials have been used in medicine to generate treatment information when evidence from randomized controlled trials (RCTs) is not available or applicable. N-of-1 study design maintains the methodological safeguards provided by RCTs (blinding, randomization and controls) yet avoids the disadvantages associated with large trials. A standardized method of reporting of N-of-1 trials, such as the Consolidated Standards of Reporting Trials (CONSORT), would greatly improve the quality and consistency of trial reports in this area. The objective of this study was to develop a CONSORT Extension for N-of-1 Trials (CENT).

#### Methods

Checklist items for the CENT guidelines were derived from three systematic reviews on N-of-1 conduct, analysis and meta-analysis. A structured process of obtaining information from a group of experts to refine and finalize the CENT guidelines was carried out. Two stages of questionnaires asked participants to rate the relative importance of suggested checklist items; the second questionnaire was refined based on feedback from the previous one. Participants included those known to have interests in either RCT reporting or N-of-1 methodology. Items included after the Delphi process were debated and finalized during an in-person meeting.

#### Results

There were 44 unique respondents between the two rounds of questionnaires. Based on questionnaire results, topics chosen for discussion at the in person meeting included: terminology (what is "N-of-1"?), randomization and blinding, research vs. clinical care, and analysis and meta-analysis. The CENT checklist was

refined and adapted to the format of the most recent CONSORT 2010 statement.

#### **Conclusion**

N-of-1 trials may promote an evidence-based approach to therapy so that families, health care providers and policy-makers can make informed choices, and are relevant to both conventional and complementary and alternative medicine. The CONSORT 'extension' will facilitate critical appraisal and interpretation of N-of-1 trials by providing authors with guidance on how to improve reporting.

#### Author details

<sup>1</sup>5University of Ottawa Evidence-based Practice Center, Ottawa, Canada. <sup>2</sup>Children's Hospital of Eastern Ontario, Ottawa, Canada. <sup>3</sup>Centre for Statistics in Medicine, Institute of Health Sciences, Oxford, United Kingdom. <sup>4</sup>University of Ottawa Evidence-based Practice Center, Ottawa, Canada. <sup>5</sup>University of Alberta, Edmonton, Canada.

Published: 12 June 2012

doi:10.1186/1472-6882-12-S1-P410

Cite this article as: Shamseer et al.: P05.50. CONSORT extension for Nof-1 trials (CENT) guidelines. BMC Complementary and Alternative Medicine 2012 12(Suppl 1):P410.

## Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit



<sup>5</sup>University of Alberta, Edmonton, Canada Full list of author information is available at the end of the article

